Refine by
Antiviral Drug Articles & Analysis
15 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion and enhancement of its comprehensive Drug Discovery Services to help scientists advance antiviral therapeutic development, including target selection and validation, hit selection and optimization, and preclinical development. ...
These nucleosides are not just helpful in generating genes but also for the production of anticancer and antiviral drugs that could make medicines that work and are well tolerated in all manner of ailments. ...
These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. Influenza A viruses are members of the Orthomyxoviridae family with a unique genome consisting of eight single-stranded negative-sense RNA fragments. ...
These proteins are antigenic when the virus infects host cells and are the primary targets of antibodies and antiviral drugs. Highly pathogenic avian influenza H5N1 viruses were first detected in domesticated waterfowl in southern China in 1996. ...
An understanding of the entry mechanism of these viruses may provide the basis for the design of antiviral drug candidates and subunit vaccines. Creative Diagnostics now offers new reagent solutions to assist researchers in herpesvirus research, including antibodies that target specific steps in the herpesvirus entry process. Scientists can utilize these ...
Then neuraminidase inhibition assays and antiviral drug activity screening will be performed to determine the 50% drug inhibitory dose. ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Phil Gomez, CEO of SIGA. “TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors; there is also the potential it could increase immunotherapeutic outcomes. ...
The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) has received guidance from the U.S. Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. ...
During the quarter ended 31 March 2022 Biotron Limited (‘Biotron’ or ‘the Company’) achieved key outcomes including: Confirmed and extended previous findings on the effectiveness of Biotron's lead antiviral drug BIT225 against SARS-CoV-2 in an animal model of human COVID-19 through demonstration of 100% survival despite administration ...
Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches -- Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready assets; Gates Foundation to contribute sector expertise in ...
(NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized ...
Drug discovery is often a laborious, and time-consuming task. Now, Creative Biolabs has optimized a portfolio of antiviral drug discovery services, especially neutralizing antibody development for SARS-CoV-2. ...
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM’s second “safe to proceed” clinical trial authorization from the FDA within the past six months and demonstrates the broad ...
The following are a few ways the StartX Med COVID-19 Task Force is working to provide hope, flatten the curve, and combat the novel coronavirus: Rapid tests suitable for drive through testing, nursing homes, and ER rooms with results in 10 minutes Applications and hardware to assess respiratory issues Rapid solutions to fight developing sepsis and correlating antibiotic resistance resulting ...